Cullinan Oncology (CGEM)

• Market cap: $694M
• 1 day: -0.42%
• 5 days: 36.04%
• 1 month: 45.66%
• 3 months: 53.66%
• 6 months: 50.13%
• Year to date: -5.25%
• 1 year: -8.07%
• 5 years: -60.75%
• 10 years: -60.75%
• Sector: Healthcare
• Industry: Biotechnology

About: Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Employees: 111